Smith Hunter C insider trades
Smith Hunter C has filed 35 Form 4s with the SEC that we hold, for Rhythm Pharmaceuticals, INC. (RYTM) (Chief Financial Officer) and Spyre Therapeutics, Inc. (AGLE) (Director). Across all of them we count 0 purchases worth $0 and 52 sales worth $19.4M reported on Form 4. In the last 12 months: 0 purchases ($0) and 26 sales ($8.8M). The largest single trade was a sale of 28,188 shares of Rhythm Pharmaceuticals, INC. worth $3.0M, dated 2026-08-31. Of 3 sales filed since we began reading the 10b5-1 checkbox, 3 (100%) were marked as made under a 10b5-1 trading plan. The first filing on our record is dated 2021-11-16 and the latest 2026-09-01.
Rhythm Pharmaceuticals, INC. (RYTM)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2022-02-15 | S, sale reported on Form 4 | 833 | $5.1K | 2022-02-15 |
| 2022-07-01 | S, sale reported on Form 4 | 7,547 | $30.8K | 2022-07-06 |
| 2023-02-09 | S, sale reported on Form 4 | 1,413 | $38.9K | 2023-02-14 |
| 2023-02-09 | S, sale reported on Form 4 | 1,398 | $38.7K | 2023-02-13 |
| 2023-02-14 | S, sale reported on Form 4 | 702 | $18.9K | 2023-02-14 |
| 2023-11-14 | S, sale reported on Form 4 | 12,000 | $364.6K | 2023-11-16 |
| 2023-11-24 | S, sale reported on Form 4 | 10,974 | $384.3K | 2023-11-28 |
| 2023-12-05 | S, sale reported on Form 4 | 7,026 | $246.3K | 2023-12-07 |
| 2023-12-06 | S, sale reported on Form 4 | 20,000 | $800.0K | 2023-12-07 |
| 2024-02-01 | S, sale reported on Form 4 | 1,616 | $72.8K | 2024-02-05 |
| 2024-02-12 | S, sale reported on Form 4 | 1,209 | $62.1K | 2024-02-13 |
| 2024-02-13 | S, sale reported on Form 4 | 709 | $35.3K | 2024-02-13 |
| 2024-03-19 | S, sale reported on Form 4 | 15,515 | $608.5K | 2024-03-19 |
| 2025-02-04 | S, sale reported on Form 4 | 1,678 | $99.7K | 2025-02-04 |
| 2025-02-11 | S, sale reported on Form 4 | 5 | $288 | 2025-02-11 |
| 2025-02-11 | S, sale reported on Form 4 | 1,291 | $74.2K | 2025-02-11 |
| 2025-02-12 | S, sale reported on Form 4 | 739 | $41.7K | 2025-02-14 |
| 2025-02-12 | S, sale reported on Form 4 | 12 | $675 | 2025-02-14 |
| 2025-02-19 | S, sale reported on Form 4 | 2,215 | $126.7K | 2025-02-19 |
| 2025-05-30 | S, sale reported on Form 4 | 18,993 | $1.2M | 2025-06-03 |
| 2025-05-30 | S, sale reported on Form 4 | 4,407 | $268.5K | 2025-06-03 |
| 2025-07-09 | S, sale reported on Form 4 | 23,400 | $2.0M | 2025-07-11 |
| 2025-07-09 | S, sale reported on Form 4 | 17,113 | $1.3M | 2025-07-11 |
| 2025-07-09 | S, sale reported on Form 4 | 1,607 | $122.4K | 2025-07-11 |
| 2025-08-12 | S, sale reported on Form 4 | 24,611 | $2.4M | 2025-08-14 |
| 2025-08-13 | S, sale reported on Form 4 | 3,477 | $333.8K | 2025-08-14 |
| 2026-02-04 | S, sale reported on Form 4 | 1,500 | $157.1K | 2026-02-06 |
| 2026-02-04 | S, sale reported on Form 4 | 747 | $80.4K | 2026-02-06 |
| 2026-02-04 | S, sale reported on Form 4 | 1,000 | $106.6K | 2026-02-06 |
| 2026-02-05 | S, sale reported on Form 4 | 3,381 | $358.6K | 2026-02-06 |
| 2026-02-10 | S, sale reported on Form 4 | 700 | $72.6K | 2026-02-12 |
| 2026-02-10 | S, sale reported on Form 4 | 100 | $10.5K | 2026-02-12 |
| 2026-02-10 | S, sale reported on Form 4 | 1,913 | $196.4K | 2026-02-12 |
| 2026-02-11 | S, sale reported on Form 4 | 2,266 | $222.9K | 2026-02-12 |
| 2026-02-11 | S, sale reported on Form 4 | 100 | $10.1K | 2026-02-12 |
| 2026-02-11 | S, sale reported on Form 4 | 400 | $39.8K | 2026-02-12 |
| 2026-02-12 | S, sale reported on Form 4 | 100 | $10.0K | 2026-02-12 |
| 2026-02-12 | S, sale reported on Form 4 | 800 | $79.2K | 2026-02-12 |
| 2026-02-12 | S, sale reported on Form 4 | 400 | $39.1K | 2026-02-12 |
| 2026-02-12 | S, sale reported on Form 4 | 292 | $28.1K | 2026-02-12 |
| 2026-02-17 | S, sale reported on Form 4 | 200 | $20.1K | 2026-02-19 |
| 2026-02-17 | S, sale reported on Form 4 | 900 | $91.5K | 2026-02-19 |
| 2026-02-17 | S, sale reported on Form 4 | 1,069 | $110.1K | 2026-02-19 |
| 2026-02-17 | S, sale reported on Form 4 | 1,200 | $119.3K | 2026-02-19 |
| 2026-02-17 | S, sale reported on Form 4 | 200 | $20.8K | 2026-02-19 |
| 2026-02-19 | S, sale reported on Form 4 | 1,308 | $131.2K | 2026-02-19 |
| 2026-02-19 | S, sale reported on Form 4 | 1,692 | $170.8K | 2026-02-19 |
| 2026-02-19 | S, sale reported on Form 4 | 800 | $81.7K | 2026-02-19 |
| 2026-02-19 | S, sale reported on Form 4 | 585 | $60.4K | 2026-02-19 |
| 2026-08-31 | S, sale reported on Form 4 | 23,072 | $2.4M | 2026-09-01 |
| 2026-08-31 | S, sale reported on Form 4 | 11,514 | $1.2M | 2026-09-01 |
| 2026-08-31 | S, sale reported on Form 4 | 28,188 | $3.0M | 2026-09-01 |
Spyre Therapeutics, Inc. (AGLE)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1636385) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms